Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocannabinoid Modulation & Neuroinflammation Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MGLL/MAGL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MGLL Full-Length Recombinant Protein (Wild-Type & S122A Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Catalytically active. |
View MGLL Products |
| Mutant Control | MGLL S122A Catalytic Dead Mutant For negative control in enzymatic assays. Sequence Verified. |
View MGLL Products |
| Gene Delivery | MGLL Promise-ORF / Lentivirus Full-length ORF for stable overexpression cell lines. |
View MGLL Products |
| Benchmark Ab | Anti-MGLL (Reference Clone) Recombinant antibody for Western/ELISA validation. |
View MGLL Products |
| Validator | MGLL siRNA Set For knockdown verification in cellular assays. |
View MGLL Products |
| FAAH | FAAH Recombinant Protein Key off-target for selectivity screening; co-regulates endocannabinoid tone. |
View FAAH Products |
| ABHD6 | ABHD6 Recombinant Protein Alternative 2-AG hydrolase; critical for selectivity panels. |
View ABHD6 Products |
| DAGLA | DAGLA Recombinant Protein 2-AG synthetic enzyme; pathway complementary target. |
View DAGLA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Serine Hydrolase Selectivity (FAAH/ABHD6/ABHD12 off-target) | Homolog Panel available: Human/Mouse MGLL, FAAH, ABHD6, ABHD12. All >95% purity, sequence verified by Mass Spec. |
| Covalent Inhibitor Residence Time Studies | Active Site Intact: Catalytic triad (Ser122, Asp239, His269) confirmed by sequence alignment. Suitable for progressive inhibition assays. |
| Cellular Validation (2-AG levels) | Gene Delivery Ready: Lentivirus particles for stable MGLL-overexpressing cell lines; siRNA for loss-of-function. |
| Mechanism of Action Delineation | Catalytic Dead Mutant: S122A mutant available as negative control for enzymatic assays. |
Live MGLL/MAGL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The MGLL/MAGL inhibitor landscape is experiencing renewed interest following the clinical setbacks of early irreversible inhibitors. Current R&D has pivoted toward peripherally restricted, reversible inhibitors to circumvent CNS-mediated adverse effects (anxiety, sedation) observed with first-generation compounds. The therapeutic focus has expanded beyond pain management into neurodegenerative diseases (Alzheimer's, MS) and metabolic disorders, leveraging MGLL's role in neuroinflammation and lipid metabolism. The next wave of R&D is targeting dual FAAH/MGLL inhibitors and tissue-specific delivery systems.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Irreversible Small Molecule | Preclinical Academic Labs | Neuropathic Pain | Covalent Binding Kinetics (Need active-site intact recombinant enzyme) |
| Reversible Small Molecule | Specialty Biotechs | Neuroinflammation (MS) | Selectivity Panel vs FAAH/ABHD6 (Need homolog proteins) |
| Dual FAAH/MGLL Inhibitor | Pain-Focused Biotech | Chronic Pain | Enzymatic Activity Assay (Both targets available for IC50 determination) |
| Protein Degradation (PROTAC) | Academic Research | Cancer (invasion) | Cellular Validation (Need lentivirus/siRNA for target engagement) |
Molecular Differentiation & Assay Strategy
Selectivity Profile
Best-in-class compounds must achieve >100-fold selectivity over FAAH, ABHD6, and ABHD12. TarMart provides a full homolog panel of recombinant proteins (HEK293-expressed, >95% purity) for high-throughput counter-screening.
Reversibility & Kinetics
Reversible inhibitors are preferred to avoid long-term off-target risks. Use wild-type MGLL (with intact catalytic triad Ser122-Asp239-His269) and S122A catalytic dead mutant for mechanism-of-action studies.
Subcellular Localization & Membrane Binding
MGLL dynamically distributes between cytosolic and membrane-associated forms. Lentivirus and siRNA tools enable cell-based assays for target engagement validation.
CNS Penetration
Peripheral restriction is critical for pain indications; controlled CNS penetration is needed for neurodegenerative diseases. PAMPA and MDCK-MDR1 assays are recommended.
Enzyme Kinetics & Lipidomics
Substrate profiling with different chain-length fluorogenic substrates or LC-MS lipidomics ensures consistent kinetic parameters (Km, kcat).